This trial is completed!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Peripheral T-cell Lymphoma (Not Otherwise Specified), Angioimmunoblastic T-cell Lymphoma, Extranodal NK/T-cell Lymphoma Nasal Type, Enteropathy- Type T-cell Lymphoma, Hepatosplenic T-cell Lymphoma, Anaplastic Large Cell Lymphoma (ALCL) (ALK-1 Negative) or Relapsed ALCL (ALK-1 Positive) Post Autologous Transplant
and you are
over 21
years old
This is a second phase trial assessing
efficacy and side effects of the new treatment.
Show me locations

The purpose

The purpose of this study is to determine whether intravenous Bortezomib combined with oral Panobinostat (LBH589) are effective in treating adult patients with relapsed/refractory peripheral T-cell lymphoma or NK/T-cell lymphoma after the failure of conventional chemotherapy.

Provided treatments

  • Drug: panobinostat and bortezomib
Tris trial is registered with FDA with number: NCT00901147. The sponsor of the trial is Singapore General Hospital and it is looking for 25 volunteers for the current phase.
Official trial title:
An Open-label Phase 2 Study of Intravenous Bortezomib and Oral Panobinostat (LBH589) in Adult Patients With Relapsed/Refractory Peripheral T-cell Lymphoma or NK/T-cell Lymphoma After Failure of Conventional Chemotherapy